We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evidence that the plant cannabinoid Δ<sup>9</sup>-tetrahydrocannabivarin is a cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptor antagonist.
- Authors
Thomas, Adèle; Stevenson, Lesley A; Wease, Kerrie N; Price, Martin R; Baillie, Gemma; Ross, Ruth A; Pertwee, Roger G
- Abstract
Δ9-tetrahydrocannabivarin (THCV) displaced [3H]CP55940 from specific binding sites on mouse brain and CHO-hCB2 cell membranes (Ki=75.4 and 62.8 nM, respectively).THCV (1 μM) also antagonized CP55940-induced stimulation of [35S]GTPγS binding to these membranes (apparent KB=93.1 and 10.1 nM, respectively).In the mouse vas deferens, the ability of Δ9-tetrahydrocannabinol (THC) to inhibit electrically evoked contractions was antagonized by THCV, its apparent KB-value (96.7 nM) approximating the apparent KB-values for its antagonism of CP55940- and R-(+)-WIN55212-induced stimulation of [35S]GTPγS binding to mouse brain membranes.THCV also antagonized R-(+)-WIN55212, anandamide, methanandamide and CP55940 in the vas deferens, but with lower apparent KB-values (1.5, 1.2, 4.6 and 10.3 nM, respectively).THCV (100 nM) did not oppose clonidine, capsaicin or (−)-7-hydroxy-cannabidiol-dimethylheptyl-induced inhibition of electrically evoked contractions of the vas deferens.Contractile responses of the vas deferens to phenylephrine hydrochloride or β,γ-methylene-ATP were not reduced by 1 μM THCV or R-(+)-WIN55212, suggesting that THCV interacts with R-(+)-WIN55212 at prejunctional sites.At 32 μM, THCV did reduce contractile responses to phenylephrine hydrochloride and β,γ-methylene-ATP, and above 3 μM it inhibited electrically evoked contractions of the vas deferens in an SR141716A-independent manner.In conclusion, THCV behaves as a competitive CB1 and CB2 receptor antagonist. In the vas deferens, it antagonized several cannabinoids more potently than THC and was also more potent against CP55940 and R-(+)-WIN55212 in this tissue than in brain membranes. The bases of these agonist- and tissue-dependent effects remain to be established.British Journal of Pharmacology (2005) 146, 917–926. doi:10.1038/sj.bjp.0706414; published online 3 October 2005
- Publication
British Journal of Pharmacology, 2005, Vol 146, Issue 7, p917
- ISSN
0007-1188
- Publication type
Academic Journal
- DOI
10.1038/sj.bjp.0706414